ENOrphanet Journal of Rare Diseases | 8-Year Clinical and Genetic Characterization of Skeletal Dysplasia Patients in Guangxi
Date: October 27, 2023
Classification: Frontiers
Recommend:
This study reveals high-frequency mutations in key genes such as FGFR3 in skeletal dysplasia, providing crucial data support for precision diagnostic strategies and genotype-phenotype correlation analysis in rare diseases.
Overview of the Literature
This article, titled "Clinical and genetic profiles of postnatal patients with skeletal dysplasia in Guangxi during 8 years: a single-center experience," published in the Orphanet Journal of Rare Diseases, systematically explores the clinical phenotypes and molecular genetic characteristics of 434 families with skeletal dysplasia (SD) in Guangxi. Through retrospective analysis, the study details the differences in diagnostic efficacy between whole-exome sequencing (WES) and Sanger sequencing, and maps the region-specific pathogenic gene spectrum.Background Knowledge
Skeletal Dysplasia is a group of highly heterogeneous genetic disorders primarily affecting the development of bones and cartilage. The biggest challenge in current clinical diagnosis lies in the complex and diverse phenotypes lacking specificity; relying solely on imaging often fails to achieve precise subtyping, leading to significant delays in diagnosis for many patients, especially those with isolated skeletal abnormalities. Although genes such as FGFR3 and COL2A1 are known to be associated with various skeletal diseases, their mutation spectra vary significantly across different populations, and the functional mechanisms of some rare variants remain unclear. Furthermore, for complex cases accompanied by neurodevelopmental delays or multi-system malformations, rapidly identifying the causative gene remains a clinical challenge. Based on this background, this study aims to clarify the genetic characteristics of skeletal dysplasia in Guangxi through large-scale cohort analysis, fill regional data gaps, and provide a basis for developing targeted genetic testing strategies.
Research Methods and Core Experiments
The research team conducted a retrospective cohort study on 434 families (totaling 455 affected individuals) who visited the Guangxi Maternal and Child Health Hospital between 2015 and 2023. The experimental system primarily utilized Whole Exome Sequencing (WES), with targeted Sanger sequencing used for validation in some cases. The team employed the Burrows-Wheeler Aligner (BWA) and GATK toolkit for data alignment and variant detection, and identified copy number variations (CNVs) through a specific CNV analysis pipeline. All candidate variants were classified for pathogenicity according to ACMG/AMP guidelines. Key evidence lies in the integration of multi-omics data, which not only identified single-gene mutations but also successfully detected chromosomal abnormalities and mosaic variants, thereby comprehensively resolving the molecular etiology of patients.Key Conclusions and Perspectives
Research Significance and Outlook
These findings have profound implications for rare disease drug development and clinical monitoring. First, identified high-frequency mutation genes (such as FGFR3) provide direct targets for developing targeted therapies against specific pathways. Second, the study highlights the issue of diagnostic delay (average age of diagnosis 5.1 years, later for females), suggesting the need to optimize clinical pathways, particularly by initiating genetic testing early for children with isolated skeletal abnormalities. Additionally, the reclassification of Variants of Uncertain Significance (VUS) and the optimization of mosaic detection technology will further improve the accuracy of disease modeling, helping families conduct more scientific genetic counseling and reproductive planning.
Conclusion
Through an in-depth analysis of 434 families with skeletal dysplasia in Guangxi, this study not only constructed a region-specific genetic mutation map but also profoundly revealed the complex relationship between clinical phenotypes and genotypes. The study confirms that while whole-exome sequencing is a powerful diagnostic tool, combining it with targeted sequencing can significantly improve diagnostic efficiency in specific scenarios. For rare diseases like skeletal dysplasia, early and precise molecular diagnosis is the cornerstone of improving patient prognosis and avoiding misdiagnosis or missed diagnosis. In the future, with deeper research into the functions of key genes such as FGFR3 and COL2A1, and the widespread adoption of multi-omics testing technologies, clinicians will be able to identify high-risk populations earlier, formulate personalized intervention plans, significantly improve patients' quality of life, and drive the rare disease diagnosis and treatment system towards precision and efficiency.
